Paul J. Clancy - Oct 21, 2021 Form 3 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
Director
Signature
/s/ Chris Frankenfield, Attorney-in-Fact
Stock symbol
XLO
Transactions as of
Oct 21, 2021
Transactions value $
$0
Form type
3
Date filed
10/21/2021, 08:44 PM
Previous filing
Oct 4, 2021
Next filing
Oct 26, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding XLO Stock Option (right to buy) Oct 21, 2021 Common Stock 23.4K $5.51 Direct F1
holding XLO Stock Option (right to buy) Oct 21, 2021 Common Stock 34.8K $5.89 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on July 23, 2020 for 23,364 shares. On July 16, 2021, 25% of the shares underlying the option vested and the remainder are scheduled to vest in equal monthly installments thereafter until July 16, 2024.
F2 The option was granted on March 11, 2021 for 34,770 shares. On July 16, 2021, 25% of the shares underlying the option vested, and the remainder are scheduled to vest in equal monthly installments thereafter until July 16, 2024.

Remarks:

Exhibit Index: 24.1 Power of Attorney